This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, College De France, National Institute of Health and Medical Research. Active years: 2018.
Company Filing History:
1 out of 5,383 
1 out of 24 
1 out of 1,853 
Years Active: 2018
Title: The Innovative Contributions of Karen Arnaud
Introduction
Karen Arnaud is a prominent inventor based in Paris, France. She has made significant strides in the field of neurodegenerative disease research, particularly in relation to Alzheimer's disease. Her work focuses on innovative treatments that aim to inhibit the synthesis of beta-amyloid precursor protein (βAPP) or the activity of the Aβ peptide in the choroid plexus.
Latest Patents
Karen Arnaud holds one patent titled "Inhibition of the synthesis of beta-app or the activity of the A-β peptide in the choroid plexus." This invention relates to the treatment of neurodegenerative diseases, specifically targeting Alzheimer's disease through the inhibition of βAPP synthesis or Aβ peptide activity.
Career Highlights
Throughout her career, Karen has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and the Collège de France. Her contributions to research and innovation have been instrumental in advancing our understanding of neurodegenerative diseases.
Collaborations
Karen has collaborated with notable colleagues, including Ariel Di Nardo and Kenneth Lee Moya. These partnerships have enriched her research and expanded the impact of her inventions.
Conclusion
Karen Arnaud's innovative work in the field of neurodegenerative diseases exemplifies the importance of research and invention in addressing critical health challenges. Her contributions continue to inspire advancements in treatment options for Alzheimer's disease.